In News

Follow this topic

Bookmark

Record learning outcomes

Cosentyx (secukinumab), a new systemic treatment for moderate to severe plaque psoriasis, has launched in the UK. Manufactured by Novartis Pharmaceuticals UK, secukinumab is the first treatment that works by blocking a protein called IL-17A, which is found in higher concentrations in the skin of people with psoriasis. In a clinical study, secukinumab demonstrated significant improvement in not only patients' skin but also their quality of life when compared to an existing NICE-recommended treatment.

Helen McAteer, Psoriasis Association chief executive, said: €Our research suggests people want treatment that will reduce the visible elements of psoriasis as well as their overall wellbeing. New treatments which achieve this, like secukinumab, will be welcomed by patients.€